{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:02:30Z","timestamp":1767049350039,"version":"3.48.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the initial surge of the COVID-19 pandemic has passed, identifying prognostic biomarkers remains critical for managing severe cases and preparing for future respiratory viral outbreaks. Asprosin, a metabolic hormone involved in energy homeostasis and inflammation, has been linked to cardiometabolic disorders, but its relationship with COVID-19 severity has not been fully elucidated. This prospective study aimed to investigate the association between serum asprosin levels, disease severity, and clinical outcomes in COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 121 participants were enrolled, including 95 hospitalized patients with RT-PCR\u2013confirmed COVID-19 and 26 PCR-negative controls. Patients were classified into mild, moderate, or severe pneumonia groups based on chest CT findings. Demographic, clinical, and laboratory parameters\u2014including serum asprosin\u2014were analyzed for differences between groups and correlations with disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum asprosin levels were significantly higher in COVID-19 patients compared to controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and served as an independent predictor of COVID-19 positivity (OR\u2009=\u20092.13,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017). ROC analysis demonstrated strong diagnostic performance (AUC\u2009=\u20090.849,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with a cut-off of 4.71 ng\/mL yielding 98.9% sensitivity and 69.2% specificity. COVID-19 patients also showed higher ferritin, CRP, and urea, and lower platelet and albumin levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Mortality was strongly associated with pneumonia severity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001); low oxygen saturation and hypertension emerged as independent predictors of severity. Asprosin correlated positively with fibrinogen and negatively with comorbidity count. Patients with diabetes mellitus had significantly lower asprosin levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042), while no significant differences were observed according to mortality status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated serum asprosin in COVID-19 patients suggests involvement in metabolic and inflammatory responses. Although unrelated to disease severity, it may aid diagnosis and reflect systemic stress. Larger multicenter studies are needed to confirm its biomarker and therapeutic potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12227-0","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:21:28Z","timestamp":1763983288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum asprosin levels as a potential prognostic biomarker in COVID-19: insights for future respiratory viral pandemics"],"prefix":"10.1186","volume":"25","author":[{"given":"Esra","family":"Erdo\u011fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azize","family":"Yeti\u015fgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"12227_CR1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=c (2023). Accessed February 10, 2024."},{"key":"12227_CR2","doi-asserted-by":"crossref","unstructured":"Tsilingiris D, Dalamaga M, Liu J. SARS-CoV-2 adipose tissue infection and hyperglycemia: a further step towards the understanding of severe COVID-19. Elsevier; 2022. p. 100163.","DOI":"10.1016\/j.metop.2022.100163"},{"key":"12227_CR3","doi-asserted-by":"crossref","unstructured":"D\u2019Souza F, Buzzetti R, Pozzilli P, Diabetes. COVID-19, and questions unsolved. Diab\/Metab Res Rev. 2023:e3666.","DOI":"10.1002\/dmrr.3666"},{"key":"12227_CR4","doi-asserted-by":"crossref","unstructured":"Fu Y, Zeng L, Huang P, Liao M, Li J, Zhang M et al. Severity-onset prediction of COVID-19 via artificial-intelligence analysis of multivariate factors. Heliyon. 2023;9(8).","DOI":"10.1016\/j.heliyon.2023.e18764"},{"issue":"3","key":"12227_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141\u201354.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"12227_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.5578\/mb.69811","volume":"54","author":"\u00d6 G\u00fcnal","year":"2020","unstructured":"G\u00fcnal \u00d6, T\u00fcre E, Bayburtlu M, Arslan U, Demira\u011f M, Ta\u015fk\u0131n M, et al. COVID-19 tan\u0131l\u0131 hastalar\u0131n risk fakt\u00f6rleri a\u00e7\u0131s\u0131ndan de\u011ferlendirilmesi. Mikrobiyol Bul. 2020;54(4):575\u201382.","journal-title":"Mikrobiyol Bul"},{"key":"12227_CR7","doi-asserted-by":"publisher","first-page":"112118","DOI":"10.1016\/j.diabres.2025.112118","volume":"223","author":"Y He","year":"2025","unstructured":"He Y, Zheng Q, Zhifang Z, Xiaofeng N, Shenggen W, Xue M, et al. When COVID-19 Meets diabetes: A bibliometric analysis. Diabetes Res Clin Pract. 2025;223:112118.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"12227_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566\u201379.","journal-title":"Cell"},{"key":"12227_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fendo.2020.00064","volume":"11","author":"M Yuan","year":"2020","unstructured":"Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel player in metabolic diseases. Front Endocrinol. 2020;11:64.","journal-title":"Front Endocrinol"},{"key":"12227_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-020-00564-w","volume":"12","author":"S Naiemian","year":"2020","unstructured":"Naiemian S, Naeemipour M, Zarei M, Lari Najafi M, Gohari A, Behroozikhah MR, et al. Serum concentration of Asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020;12:1\u20138.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"12227_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/nu13020620","volume":"13","author":"AI Mazur-Bialy","year":"2021","unstructured":"Mazur-Bialy AI. Asprosin\u2014a fasting-induced, glucogenic, and orexigenic adipokine as a new promising player. Will it be a new factor in the treatment of obesity, diabetes, or infertility? A review of the literature. Nutrients. 2021;13(2):620.","journal-title":"Nutrients"},{"key":"12227_CR12","doi-asserted-by":"publisher","first-page":"e63784","DOI":"10.7554\/eLife.63784","volume":"10","author":"I Mishra","year":"2021","unstructured":"Mishra I, Duerrschmid C, Ku Z, He Y, Xie W, Silva ES, et al. Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. Elife. 2021;10:e63784.","journal-title":"Elife"},{"key":"12227_CR13","doi-asserted-by":"publisher","first-page":"1101091","DOI":"10.3389\/fendo.2022.1101091","volume":"13","author":"M Farrag","year":"2023","unstructured":"Farrag M, Ait Eldjoudi D, Gonz\u00e1lez-Rodr\u00edguez M, Cordero-Barreal A, Ruiz-Fern\u00e1ndez C, Capuozzo M, et al. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol. 2023;13:1101091.","journal-title":"Front Endocrinol"},{"key":"12227_CR14","doi-asserted-by":"publisher","first-page":"907358","DOI":"10.3389\/fphys.2022.907358","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Liu Y, Huang M, Zhang M, Zhu C, Chen X, et al. The effects of Asprosin on exercise-intervention in metabolic diseases. Front Physiol. 2022;13:907358.","journal-title":"Front Physiol"},{"key":"12227_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12079-020-00566-3","volume":"14","author":"ML Muthu","year":"2020","unstructured":"Muthu ML, Reinhardt DP. Fibrillin-1 and fibrillin-1-derived Asprosin in adipose tissue function and metabolic disorders. J Cell Communication Signal. 2020;14:159\u201373.","journal-title":"J Cell Communication Signal"},{"issue":"1","key":"12227_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-025-10842-3","volume":"52","author":"MM Erdo\u011fan","year":"2025","unstructured":"Erdo\u011fan MM, Erdo\u011fan E, Kocaman N, Telo S, Bi\u00e7en H, Erdo\u011fdu H, et al. Effects of Nerolidol on serum cytokines in acute myocardial infarction: insights into the asprosin, spexin, and DARS2 antibodies in the brain cortex. Mol Biol Rep. 2025;52(1):1\u201311.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"12227_CR17","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11325-021-02298-z","volume":"25","author":"J Ding","year":"2021","unstructured":"Ding J, Wang S, Tan W, Song X, Zhang L. Association of serum Asprosin concentrations with obstructive sleep apnea syndrome. Sleep Breath. 2021;25(4):1893\u20136.","journal-title":"Sleep Breath"},{"issue":"4","key":"12227_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2337\/dbi19-0009","volume":"69","author":"JG Hoffmann","year":"2020","unstructured":"Hoffmann JG, Xie W, Chopra AR. Energy regulation mechanism and therapeutic potential of Asprosin. Diabetes. 2020;69(4):559\u201366.","journal-title":"Diabetes"},{"key":"12227_CR19","doi-asserted-by":"crossref","unstructured":"Erdogan MM, Erdogan E. Analysis of semen parameters of recovered patients after COVID-19. 2023.","DOI":"10.5455\/annalsmedres.2022.10.317"},{"issue":"1","key":"12227_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12902-025-01843-1","volume":"25","author":"X Zeng","year":"2025","unstructured":"Zeng X, Sun X, He W, Xie J, Xin C. Relationship of Asprosin and diabetes: a meta-analysis. BMC Endocr Disorders. 2025;25(1):15.","journal-title":"BMC Endocr Disorders"},{"key":"12227_CR21","doi-asserted-by":"crossref","unstructured":"Seyhanli ES, Koyuncu I, Yasak IH, Demir HA, Temiz E. Asprosin and oxidative stress level in COVID-19 patients. Clin Lab. 2022;68(1).","DOI":"10.7754\/Clin.Lab.2021.210423"},{"key":"12227_CR22","unstructured":"World Health Organization.: https:\/\/covid19.who.int (2022). Accessed."},{"issue":"S1","key":"12227_CR23","first-page":"474","volume":"13","author":"LA Delen","year":"2021","unstructured":"Delen LA, Erdo\u011fan E, Ya\u015far \u015e. The risk factors affecting length of stay and mortality in Covid 19 patients: laboratory Parameters, Comorbidities, and demographic characteristics. Konuralp Med J. 2021;13(S1):474\u20138.","journal-title":"Konuralp Med J"},{"issue":"5","key":"12227_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40618-022-01742-5","volume":"45","author":"A Basolo","year":"2022","unstructured":"Basolo A, Poma A, Bonuccelli D, Proietti A, Macerola E, Ugolini C, et al. Adipose tissue in COVID-19: detection of SARS-CoV-2 in adipocytes and activation of the interferon-alpha response. J Endocrinol Investig. 2022;45(5):1021\u20139.","journal-title":"J Endocrinol Investig"},{"issue":"13","key":"12227_CR25","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/cells11132109","volume":"11","author":"F Cinti","year":"2022","unstructured":"Cinti F, Cinti S. The endocrine adipose organ: A system playing a central role in COVID-19. Cells. 2022;11(13):2109.","journal-title":"Cells"},{"key":"12227_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cca.2017.10.034","volume":"489","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating Asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183\u20138.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"12227_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s00403-025-04099-w","volume":"317","author":"MM Erdogan","year":"2025","unstructured":"Erdogan MM, Erdogan E, Kocaman N, Yasar S, Kavak SY. The diagnostic potential of Asprosin and Meteorin-like proteins in basal and squamous cell carcinomas. Arch Dermatol Res. 2025;317(1):574.","journal-title":"Arch Dermatol Res"},{"key":"12227_CR28","doi-asserted-by":"publisher","first-page":"826006","DOI":"10.3389\/fcdhc.2022.826006","volume":"3","author":"A Gerganova","year":"2022","unstructured":"Gerganova A, Assyov Y, Kamenov Z. Stress hyperglycemia, diabetes mellitus and COVID-19 infection: risk factors, clinical outcomes and post-discharge implications. Front Clin Diabetes Healthc. 2022;3:826006.","journal-title":"Front Clin Diabetes Healthc"},{"issue":"1","key":"12227_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/ijms24010227","volume":"24","author":"K Shabir","year":"2022","unstructured":"Shabir K, Gharanei S, Orton S, Patel V, Chauhan P, Karteris E, et al. Asprosin exerts Pro-Inflammatory effects in THP-1 macrophages mediated via the Toll-like receptor 4 (TLR4) pathway. Int J Mol Sci. 2022;24(1):227.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"12227_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10753-022-01761-7","volume":"46","author":"Q Huang","year":"2023","unstructured":"Huang Q, Chen S, Xiong X, Yin T, Zhang Y, Zeng G, et al. Asprosin exacerbates endothelium inflammation induced by hyperlipidemia through activating IKK\u03b2-NF-\u03baBp65 pathway. Inflammation. 2023;46(2):623\u201338.","journal-title":"Inflammation"},{"issue":"7","key":"12227_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/v17070957","volume":"17","author":"S K\u00f6nig","year":"2025","unstructured":"K\u00f6nig S, Vaskyte U, Boesing M, L\u00fcthi-Corridori G, Leuppi JD. The role of comorbidities in COVID-19 severity. Viruses. 2025;17(7):957.","journal-title":"Viruses"},{"key":"12227_CR32","doi-asserted-by":"crossref","unstructured":"Ulloque-Badaracco JR, Al-kassab-C\u00f3rdova A, Hernandez-Bustamante EA, Alarcon-Braga EA, Robles-Valcarcel P, Huayta-Cortez MA et al. Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: a systematic review and meta-analysis. Diabetes Metab Syndr: Clinical Research & Reviews. 2024;18(7):103095.","DOI":"10.1016\/j.dsx.2024.103095"},{"key":"12227_CR33","doi-asserted-by":"publisher","first-page":"731974","DOI":"10.3389\/fendo.2021.731974","volume":"12","author":"S Shao","year":"2021","unstructured":"Shao S, Yang Q, Pan R, Yu X, Chen Y. Interaction of severe acute respiratory syndrome coronavirus 2 and diabetes. Front Endocrinol. 2021;12:731974.","journal-title":"Front Endocrinol"},{"issue":"6","key":"12227_CR34","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.3390\/ijms24065745","volume":"24","author":"AI Mazur-Bialy","year":"2023","unstructured":"Mazur-Bialy AI. Asprosin enhances cytokine production by a Co-Culture of fully differentiated mature adipocytes and macrophages leading to the exacerbation of the condition typical of Obesity-Related inflammation. Int J Mol Sci. 2023;24(6):5745.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12227_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12879-023-08573-6","volume":"23","author":"L Verdiguel-Fern\u00e1ndez","year":"2023","unstructured":"Verdiguel-Fern\u00e1ndez L, Arredondo-Hern\u00e1ndez R, Mej\u00eda-Estrada JA, Ortiz A, Verdugo-Rodr\u00edguez A, Ordu\u00f1a P, et al. Differential expression of biomarkers in saliva related to SARS-CoV-2 infection in patients with mild, moderate and severe COVID-19. BMC Infect Dis. 2023;23(1):602.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"12227_CR36","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1002\/jmv.26902","volume":"93","author":"G Guner Ozenen","year":"2021","unstructured":"Guner Ozenen G, Sahbudak Bal Z, Umit Z, Bilen NM, Yildirim Arslan S, Yurtseven A, et al. Demographic, clinical, and laboratory features of COVID-19 in children: the role of mean platelet volume in predicting hospitalization and severity. J Med Virol. 2021;93(5):3227\u201337.","journal-title":"J Med Virol"},{"key":"12227_CR37","unstructured":"Karaca Karagoz Z, Aydin S. Effects of oxygen saturation on the hypoxia-inducible factor-1\u03b1, subfatin, asprosin, irisin, c-reactive protein, maresin-1, and Diamine oxidase in diabetic patients with COVID-19. Eur Rev Med Pharmacol Sci. 2022;26(24)."},{"issue":"1","key":"12227_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12872-020-01680-1","volume":"20","author":"M-S Wen","year":"2020","unstructured":"Wen M-S, Wang C-Y, Yeh J-K, Chen C-C, Tsai M-L, Ho M-Y, et al. The role of Asprosin in patients with dilated cardiomyopathy. BMC Cardiovasc Disord. 2020;20(1):402.","journal-title":"BMC Cardiovasc Disord"},{"key":"12227_CR39","doi-asserted-by":"publisher","first-page":"734005","DOI":"10.3389\/fcimb.2021.734005","volume":"11","author":"J Sui","year":"2021","unstructured":"Sui J, Noubouossie DF, Gandotra S, Cao L. Elevated plasma fibrinogen is associated with excessive inflammation and disease severity in COVID-19 patients. Front Cell Infect Microbiol. 2021;11:734005.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"12227_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/jmv.25770","volume":"92","author":"Y Gao","year":"2020","unstructured":"Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791\u20136.","journal-title":"J Med Virol"},{"issue":"8","key":"12227_CR41","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/jth.14942","volume":"18","author":"J Thachil","year":"2020","unstructured":"Thachil J. The protective rather than prothrombotic fibrinogen in COVID-19 and other inflammatory States. J Thromb Haemost. 2020;18(8):1849\u201352.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"12227_CR42","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1186\/s12903-025-06014-1","volume":"25","author":"S Tutu\u015f","year":"2025","unstructured":"Tutu\u015f S, Tan\u0131k A, Arpa\u011f OF, \u00d6nderci M. Is there a relationship between periodontal conditions and Asprosin levels in gingival crevicular fluid, saliva and serum? BMC Oral Health. 2025;25(1):651.","journal-title":"BMC Oral Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12227-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:58:31Z","timestamp":1767049111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12227-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12227"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12227-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Clinical Research Ethics Committee of Turgut \u00d6zal University (Decision No: 2022\/45). All participants were provided with detailed information about the study, and written informed consent was obtained from those who agreed to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the authors used the software ChatGPT to enhance readability and language quality. Following the use of this tool, the authors carefully reviewed and edited the content as necessary and take full responsibility for the final content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1809"}}